Silexion Therapeutics Corp. has entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to offer and sell up to $13.17 million of its ordinary shares through Wainwright as sales agent. The shares will be sold from time to time at prevailing market prices under a shelf registration statement on Form S-3, once declared effective by the SEC. Wainwright will receive a 3% commission on the gross sales price of any shares sold, and Silexion has agreed to reimburse certain expenses and provide customary indemnification. The company is not required to sell any shares under the agreement, and the offering will terminate upon the sale of all shares or termination of the agreement by either party.